Tags

Type your tag names separated by a space and hit enter

Clinical Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis

Abstract

The objective of this review is to perform a systematic review of the beneficial and harmful effects of edaravone for the treatment of amyotrophic lateral sclerosis.

Links

  • NCBI Bookshelf
  • Publisher

    Canadian Agency for Drugs and Technologies in Health
    Ottawa (ON)

    Language

    eng

    PubMed ID

    31206286

    Citation

    Clinical Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis. Canadian Agency for Drugs and Technologies in Health, 2019, Ottawa (ON).
    Clinical Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.
    (2019). In Clinical Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health;
    Clinical Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.
    * Article titles in AMA citation format should be in sentence-case
    TY - BOOK T1 - Clinical Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis Y1 - 2019/04// PY - 2019/6/18/pubmed PY - 2019/6/18/medline PY - 2019/6/18/entrez N2 - The objective of this review is to perform a systematic review of the beneficial and harmful effects of edaravone for the treatment of amyotrophic lateral sclerosis. PB - Canadian Agency for Drugs and Technologies in Health CY - Ottawa (ON) UR - https://www.unboundmedicine.com/medline/citation/31206286/Clinical_Review_Report:_Edaravone_(Radicava):_(Mitsubishi_Tanabe_Pharma_Corporation):_Indication:_For_the_treatment_of_amyotrophic_lateral_sclerosis L2 - https://www.ncbi.nlm.nih.gov/books/NBK542359 DB - PRIME DP - Unbound Medicine ER -
    Unbound Prime app for iOS iPhone iPadUnbound PubMed app for AndroidAlso Available:
    Unbound MEDLINE
    Unbound PubMed app for WindowsUnbound PubMed app for MAC OSX Yosemite Macbook Air pro